Diabetes Mellitus Type 2 Clinical Trial
Official title:
Online Support for Diabetes Self-Management
The purpose of this study is to evaluate the effect of online support for diabetes self-management for patients with Type II diabetes in the Vancouver region. Patients will be invited to receive 8 online video consultations (total 2.5 hours) with certified healthcare providers (video calls in a secure Website). Participants will also have access to the use of an online personal health record -- a place to store healthcare information for the patient and healthcare provider to view. Patients' ability to care for their diabetes will be measured at the beginning and the end of the study. Additional measures include glycaemic control, BMI, waist circumference, diabetes self-efficacy, computer and health literacy, patient satisfaction with care and perceived ease of use and perceived usefulness of the technology.
Purpose:
The purpose of this study is to evaluate the effectiveness of a 3-month control-theory-based
online support intervention consisting of 8 online video teleconsultations and access to a
secure online personal health record on self-management behaviours of adults with type 2
diabetes, as measured by the Summary of Diabetes Self-Care Activities (SDSCA). Secondary
outcomes will include glycemic control, BMI, waist circumference, diabetes self-efficacy,
computer and health literacy, patient satisfaction with care and perceived ease of use and
perceived usefulness of the technology.
Hypothesis:
Patients who receive online support for diabetes self-management and access to an online
personal health record will have higher self-management of diabetes scores after they
receive the intervention compared to before the intervention.
Justification:
In British Columbia (BC), an estimated 10.3 percent of the population is expected to have
diabetes by 2020, at an estimated cost to the BC healthcare system of 1.9 billion dollars
per year. Enhancing diabetes self-management has been estimated to be the single most
cost-effective intervention in the primary care setting. Results of telemedicine
interventions for management of diabetes have been mixed; many interventions show promising
improvement in health behaviours, self-efficacy and glycaemic control, while others show
small or no effects. A 2015 meta-analysis of the clinical effectiveness of telemedicine
randomized controlled trials for type 2 diabetes found a significant decrease in HbA1C
overall, with the largest decrease being amongst Internet-based interventions. A recent
Cochrane systematic review and meta-analysis of computer-based self-management interventions
for adults with type 2 diabetes found that interventions using mobile phones showed a
greater reduction in glycaemic control than did the telehealth interventions overall. A
meta-regression of techniques in 122 healthy eating and physical activity self-management
interventions for diabetes found that self-monitoring explained the greatest amount of
among-study heterogeneity, accounting for 13% of these differences. Self-monitoring is a
component of control theory, which proposes that in order to effectively manage behaviour,
there must be a clear, realistic goal, an action plan for attaining it, a means of
monitoring whether a person is on track, feedback, and opportunities for reviewing goals in
the light of feedback. Providing additional information for behavioural providers through an
online personal health record, and integrating behavioural support with ongoing primary care
through shared action plans, the effectiveness of behavioural support provided online may be
increased. Standard treatment primarily involves management of diabetes through medications
and may involve referral to a diabetes education centre for education about diabetes
self-management. The best method to support patient self-management has not been clearly
identified.
Objectives:
The specific outcome to be examined is self-management of type II diabetes as measured by
the Summary of Diabetes Self-Care Activities (SDSCA).
Research Method:
A pre-post intervention study with a multicentre cohort of 125 patients who will be provided
with an online support intervention and followed over three months to evaluate change in
diabetes self-management behaviours and clinical outcomes. We will recruit a total of 125
patients with type 2 diabetes through 12 participating primary care physicians. After
consent is obtained, participants will be provided with training to use the glucometer,
online video teleconsultation tools and online personal health record.
Online Support Intervention:
The online support intervention is designed as a supplement to usual care provided by the
family physician, and will be delivered via the Internet through the company Treatment, Inc.
a West Vancouver-based provider of patient self-care solutions and services (see Treatment
Diabetes Screen shots). The three-month online support intervention involves two primary
components to facilitate patient self-management: 8 online video teleconsultations with a
certified health professional (for a total of 2.5 hours, weekly at first, then bi-monthly)
and access to an online personal health record to promote health care behavioural change.
Certified healthcare professionals will provide the 8 online video teleconsultations and
will provide reports to the primary care provider as needed and at the end of the 3-month
intervention. Participants will also be given a glucose meter (Bayer Contour® Next meter)
from which glucose readings can be uploaded to the online personal health record. The
patient will use their own glucometer strips as provided by the BC government prescription
plan.
Data Collection:
The primary outcome is change in diabetes self-management behaviour as measured by the
Summary of Diabetes Self-Care Activities (SDSCA) which includes diet, exercise,
self-monitoring of blood glucose, foot care and smoking. Secondary outcomes include change
in HbA1C, BMI and waist circumference, diabetes self-efficacy, satisfaction with care, and
acceptance of using technology for online support. (See attached document: Measurement
Instruments) The primary care provider will have access to the patient's online information,
including self-monitored glucose values, for review. Participants will complete online
questionnaires at baseline and at end of study.
Sample Size Calculation:
The statistical power for the study was modeled with a two-tailed paired sample t-test to
test changes in SDSCA from baseline to three months. Published studies using the SDSCA have
shown effects sizes of change in intervention groups ranging from .278 to .53. Thus,
conservatively estimating an effect size of .278, to achieve 80% power at a p <.05
significance level, a sample of 125 participants will be required, assuming a 20%
longitudinal attrition rate. Attrition rates in the 10% to 20% range have been reported in
previous similar Web-based intervention studies.
Data Analysis:
Two-tailed paired sample t-tests will be performed to test for changes in mean
self-management behaviours from baseline to three months. Correlations will explore
relations between the outcome variables and health literacy, computer literacy and the
control variables. Changes across time in the secondary outcomes (clinical outcomes,
diabetes self-efficacy) will also be examined using paired-sample t-tests to explore for
trends and effect sizes for future studies. All tests will be performed using SPSS version
23, with a p <.05 significance level.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01267448 -
Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
|
Phase 4 | |
| Active, not recruiting |
NCT05330247 -
Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study
|
N/A | |
| Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
| Terminated |
NCT02373865 -
Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT01741181 -
Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2
|
Phase 4 | |
| Completed |
NCT01305434 -
Mulberry Leaf Extract and Blood Glucose Control in Diabetics
|
Phase 1/Phase 2 | |
| Completed |
NCT01330121 -
Bridging the Gap by Transitional Care
|
N/A | |
| Recruiting |
NCT00992797 -
Diabetes Intervention Trial With Vitamin D in Subjects of Nordic and Sub-Indian Ethnicity
|
Phase 2 | |
| Completed |
NCT01580904 -
Impact of Pharmaceutical Care in Diabetics Patients
|
N/A | |
| Active, not recruiting |
NCT00728403 -
Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes
|
Phase 2 | |
| Completed |
NCT00763815 -
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
|
Phase 3 | |
| Active, not recruiting |
NCT00529815 -
Continuous Glucose Monitoring in Patients With Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT00517465 -
A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
|
Phase 1 | |
| Withdrawn |
NCT00417716 -
Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
|
Phase 3 | |
| Completed |
NCT00119041 -
Diabetes Telemedicine Consultation: A Systems Improvement Intervention
|
N/A | |
| Withdrawn |
NCT00600236 -
HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population
|
Phase 3 | |
| Active, not recruiting |
NCT05887635 -
Study of Duodenal Mucosal RF Vapor Ablation in Subjects With Type-2 Diabetes Mellitus
|
N/A | |
| Completed |
NCT03903965 -
Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery.
|
||
| Completed |
NCT02666924 -
Cooking Classes for Chinese Canadian Patients Living With Diabetes
|
N/A | |
| Recruiting |
NCT02501850 -
The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)
|
Phase 4 |